What question did this study set out to answer?

Evaluate recent advances in advanced nanocarrier design and delivery strategies for cancer therapy while assessing key biological, manufacturing, and regulatory barriers to clinical translation.

September 17, 2026Journal of Drug Delivery and TherapeuticsOpen Access

Advanced Nanocarriers for Cancer Therapies: Recent Developments and Clinical Challenges

View Full Paper

Ask AI

Bookmark

Authors

ARAliya Rehmani PRPalak Ghanshyam Rahangdale PMPayal Dilip Meshram

Discussion

Member takes

Overview

Review demonstrates enhanced antitumor delivery and reduced toxicity via engineered nanocarriers in oncology, highlighting translation hurdles like scalability and regulation.

Key Points

Evaluate recent advances in advanced nanocarrier design and delivery strategies for cancer therapy while assessing key biological, manufacturing, and regulatory barriers to clinical translation.
Literature review and comparative analysis of lipid-based, polymeric, inorganic, biomimetic, and hybrid nanocarrier platforms for oncology applications.
Evaluation of design principles, targeting mechanisms, therapeutic efficacy, biosafety considerations, manufacturing scalability, and regulatory approval pathways.
Lipid, polymeric, inorganic, biomimetic, and hybrid systems enhance drug solubility, optimize pharmacokinetics, and increase tumor accumulation while attenuating systemic toxicity.
Stimuli-responsive and multifunctional platforms improve precision targeting, although clinical adoption remains hindered by complex manufacturing, safety assessment challenges, and rigorous regulatory hurdles.

Cite This Study

Rehmani et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6c75f706d05830e55a7 https://doi.org/10.22270/jddt.v16i9.7989

View Full Paper

Ask AI

Bookmark

September 17, 2026Journal of Drug Delivery and TherapeuticsOpen Access

Advanced Nanocarriers for Cancer Therapies: Recent Developments and Clinical Challenges

View Full Paper

Ask AI

Bookmark

Authors

ARAliya Rehmani PRPalak Ghanshyam Rahangdale PMPayal Dilip Meshram

Discussion

Member takes

Overview

Review demonstrates enhanced antitumor delivery and reduced toxicity via engineered nanocarriers in oncology, highlighting translation hurdles like scalability and regulation.

Key Points

Evaluate recent advances in advanced nanocarrier design and delivery strategies for cancer therapy while assessing key biological, manufacturing, and regulatory barriers to clinical translation.
Literature review and comparative analysis of lipid-based, polymeric, inorganic, biomimetic, and hybrid nanocarrier platforms for oncology applications.
Evaluation of design principles, targeting mechanisms, therapeutic efficacy, biosafety considerations, manufacturing scalability, and regulatory approval pathways.
Lipid, polymeric, inorganic, biomimetic, and hybrid systems enhance drug solubility, optimize pharmacokinetics, and increase tumor accumulation while attenuating systemic toxicity.
Stimuli-responsive and multifunctional platforms improve precision targeting, although clinical adoption remains hindered by complex manufacturing, safety assessment challenges, and rigorous regulatory hurdles.

Cite This Study

Rehmani et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6c75f706d05830e55a7 https://doi.org/10.22270/jddt.v16i9.7989

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark